Seagen Inc.: management transactions · United States · SEC (Form 4)

About Seagen Inc.

Seagen Inc. was a U.S.-based biopharmaceutical company focused on precision oncology, formerly listed on the NYSE/NASDAQ under ticker SGEN and headquartered in Bothell, Washington, United States. Before being taken out of public markets, the company had established itself as a leading specialist in targeted cancer medicines, with a particularly strong reputation in antibody-drug conjugates (ADCs), a drug class designed to deliver cytotoxic payloads directly to cancer cells while limiting off-target exposure. Founded in the late 1990s as Seattle Genetics, the company spent decades building a research-and-development platform centered on oncology innovation, strategic licensing, and late-stage clinical execution. In 2020, it changed its corporate name to Seagen Inc. to better reflect its broader identity and international ambitions in cancer therapeutics. ([nasdaq.com](https://www.nasdaq.com/press-release/seattle-genetics-inc.-announces-corporate-name-change-to-seagen-inc.-2020-10-08?utm_source=openai)) Commercially, Seagen’s value proposition was anchored by a portfolio of approved oncology medicines: ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin), TIVDAK® (tisotumab vedotin), and TUKYSA® (tucatinib). These therapies address multiple segments of oncology, including hematologic malignancies and solid tumors, giving the company a diversified, specialty-focused revenue base for a biotech of its size. Seagen’s differentiation came from its core platform expertise in ADC technology, which the company helped pioneer and industrialize. That platform became a strategic asset across discovery, development, and partnering, enabling Seagen to participate in several major oncology programs through a mix of direct commercialization and collaborations with larger pharma partners. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen?utm_source=openai)) From a competitive standpoint, Seagen occupied a distinctive position: it was smaller than major global pharmaceutical companies, but more mature than a typical clinical-stage biotech because it already had marketed products and meaningful development assets. That combination made it both a commercial oncology player and a high-value innovation platform. Its geographic footprint was global in reach but operationally centered in North America, with commercialization and licensing relationships extending into Europe and parts of Asia through partners. The company’s structure reflected a common biotech strategy: keep core scientific leadership in the United States while using partnerships to broaden international access and market penetration. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-43-billion-battle-cancer?utm_source=openai)) The major recent corporate event was Pfizer’s acquisition of Seagen, announced and then completed on December 14, 2023 for about $43 billion. As a result, Seagen ceased to trade as an independent public company, and its assets were folded into Pfizer’s oncology organization. For investors, that means Seagen should now be viewed as a legacy oncology franchise whose commercial products and technology platform strengthen Pfizer’s long-term cancer strategy rather than as a standalone equity story. The key takeaway is that Seagen’s scientific franchise remains highly relevant, but the listing itself no longer exists as an independent U.S. public equity. ([pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen?utm_source=openai))